# Presidio Medical, Inc.

> Presidio Medical is a clinical-stage medical device company in San Mateo, California, developing a proprietary Ultra Low Frequency (ULF) neuromodulation platform. By delivering very low frequency biphasic electrical currents through leads implanted in the epidural space, Presidio's spinal cord stimulation system reversibly blocks the conduction of pain signals along nerves without damaging tissue. Its first target is chronic nociceptive low back pain, a large and underserved indication with no approved SCS therapy. Backed by Deerfield Management and others, the company raised a $72M Series C in 2023 and received FDA IDE approval in 2025 to run its global pivotal FULFILL trial.

- **Founded:** 2017
- **Headquarters:** San Mateo, California, United States
- **Founders:** Kenneth Wu (Co-founder), Michael Ackermann (Co-founder, Board Member)
- **Team size:** ~42 employees
- **Products:** ULF Neuromodulation System, FULFILL Study
- **Notable:** Published ULF neuromodulation research in Science Translational Medicine (2021), demonstrating reversible axonal conduction block., Early 2-week human trial in 20 subjects reported pain rating improvements of roughly 90%, returning toward baseline after lead explant - indicating reversibility., Closed a $72M Series C led by Deerfield Management in June 2023.

## Products & services

- **ULF Neuromodulation System** — An investigational spinal cord stimulation (SCS) platform that delivers Ultra Low Frequency biphasic electrical currents via leads implanted in the epidural space to reversibly block the conduction of pain signals along nerves without damaging tissue. First indication: chronic nociceptive low back pain.
- **FULFILL Study** — A global, pivotal, randomized controlled clinical trial (US and Australia) evaluating the safety and efficacy of the ULF neuromodulation platform for chronic nociceptive low back pain, enabled by FDA IDE approval.

## Achievements

- Published ULF neuromodulation research in Science Translational Medicine (2021), demonstrating reversible axonal conduction block.
- Early 2-week human trial in 20 subjects reported pain rating improvements of roughly 90%, returning toward baseline after lead explant - indicating reversibility.
- Closed a $72M Series C led by Deerfield Management in June 2023.
- Received FDA IDE approval in 2025 to launch the global pivotal FULFILL randomized controlled trial in the US and Australia.
- Published additional preclinical research (2025) showing ULF waveforms inhibit sensory signaling to the thalamus in a model of neuropathic pain.

## Latest updates

- **2025-06** — Received FDA IDE approval to begin the global pivotal FULFILL study and appointed Dimas Jimenez as Chief Financial Officer.
- **2024-12** — Appointed Richard J. Buchholz to its Board of Directors.
- **2023-06** — Announced a $72M Series C equity fundraising led by Deerfield Management.
- **2021-08** — Announced publication of ULF neuromodulation research in Science Translational Medicine.

## Links

- Website: https://presidiomedical.com
- LinkedIn: http://www.linkedin.com/company/presidio-medical-inc
- Twitter/X: https://twitter.com/PresidioMedical

---

Profile page: https://yespress.io/presidio-medical-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-18